Log in

NASDAQ:BCELAtreca Stock Price, Forecast & News

$22.71
+0.61 (+2.76 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$22.01
Now: $22.71
$22.78
50-Day Range
$16.33
MA: $19.10
$23.45
52-Week Range
$9.51
Now: $22.71
$29.35
Volume108,702 shs
Average Volume241,862 shs
Market Capitalization$639.06 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. Atreca, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BCEL
CUSIPN/A
CIKN/A
Phone650-595-2595

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.68 per share

Profitability

Net Income$-67,480,000.00

Miscellaneous

Employees85
Market Cap$639.06 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive BCEL News and Ratings via Email

Sign-up to receive the latest news and ratings for BCEL and its competitors with MarketBeat's FREE daily newsletter.

Atreca (NASDAQ:BCEL) Frequently Asked Questions

How has Atreca's stock been impacted by COVID-19 (Coronavirus)?

Atreca's stock was trading at $17.62 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BCEL shares have increased by 28.9% and is now trading at $22.71. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Atreca?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atreca in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Atreca.

When is Atreca's next earnings date?

Atreca is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Atreca.

How were Atreca's earnings last quarter?

Atreca (NASDAQ:BCEL) announced its quarterly earnings results on Thursday, May, 14th. The company reported ($0.73) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.73). View Atreca's earnings history.

What price target have analysts set for BCEL?

9 brokerages have issued 12-month price objectives for Atreca's shares. Their forecasts range from $16.63 to $33.00. On average, they anticipate Atreca's stock price to reach $27.80 in the next year. This suggests a possible upside of 22.4% from the stock's current price. View analysts' price targets for Atreca.

Has Atreca been receiving favorable news coverage?

Media headlines about BCEL stock have trended negative on Sunday, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Atreca earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the near future. View the latest news about Atreca.

Who are some of Atreca's key competitors?

What other stocks do shareholders of Atreca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atreca investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), AbbVie (ABBV), Akoustis Technologies (AKTS), Homology Medicines (FIXX), II-VI (IIVI), Kaleido Biosciences (KLDO), Stoke Therapeutics (STOK) and Akero Therapeutics (AKRO).

Who are Atreca's key executives?

Atreca's management team includes the following people:
  • Mr. John A. Orwin, Pres, CEO & Director (Age 54)
  • Dr. Tito A. Serafini, Co-Founder, Board Member & Chief Strategy Officer (Age 56)
  • Mr. Herbert C. Cross, Chief Financial Officer (Age 47)
  • Dr. Yann Chong Tan, Chief Technologist
  • Dr. Guy Cavet Ph.D., Chief Technical Officer (Age 45)

When did Atreca IPO?

(BCEL) raised $126 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel served as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers.

What is Atreca's stock symbol?

Atreca trades on the NASDAQ under the ticker symbol "BCEL."

How do I buy shares of Atreca?

Shares of BCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Atreca's stock price today?

One share of BCEL stock can currently be purchased for approximately $22.71.

How big of a company is Atreca?

Atreca has a market capitalization of $639.06 million. The company earns $-67,480,000.00 in net income (profit) each year or ($4.26) on an earnings per share basis. Atreca employs 85 workers across the globe.

What is Atreca's official website?

The official website for Atreca is www.atreca.com.

How can I contact Atreca?

Atreca's mailing address is 500 SAGINAW DRIVE FIRST FLOOR, REDWOOD CITY CA, 94063. The company can be reached via phone at 650-595-2595 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.